X
Jun 28, 2021 10:07 AM (GMT+8) · EqualOcean
Recently, Jiangsu Huayang Pharmaceutical Co., Ltd. (hereinafter referred to as "Huayang pharmaceutical") has completed the strategic investment in Suzhou Antian Shengshi Pharmaceutical Technology Co., Ltd., invested tens of millions of yuan in the strategic layout of the research and development of ASO innovative drugs. As the chief scientist of Huayang pharmaceutical research Aso, Professor Hua Yimin is fully responsible for the research of ASO innovative drugs. Small nucleic acid drugs are another major drug research and development field after small molecular drugs and large molecular protein drugs. Different from the way that small molecular drugs and large molecular protein drugs act on proteins, small nucleic acid drugs act on the mRNA level, increasing the types of drug targets, greatly expanding the space of drug research and development, which is considered to be the third wave of modern pharmacy. Since its wholly-owned acquisition by Anhong Yuanhua fund of Anhong capital in March 2018, Huayang pharmaceutical has actively and strategically laid out the field of small nucleic acid drugs, and organized research and development backbones to conduct comprehensive exploration and in-depth research in this field. Huayang pharmaceutical was founded in 2002, with a total investment of 600 million yuan and a construction area of 30000 square meters. The plant and supporting facilities are designed and constructed in accordance with the new version of GMP standards. It has first-class production equipment and experimental instruments at home and abroad, and focuses on the R & D, production and sales of respiratory tract, digestive tract, cardiovascular, antiallergic and tumor drugs. At present, it has more than 300 employees, It is a high-tech enterprise recognized by the state.

This text is a result of machine translation.